-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Yabao Pharmaceutical's 4 generic drug sorafenib tosylate tablets was officially approved for marketing.
This approval proves that the safety, effectiveness, and quality controllability of the drug have reached the "Pharmaceuticals of the People's Republic of China".
The relevant provisions of the "Administrative Law" meet the requirements for drug approval and registration
.
According to reports, Sorafenib tablets are Yabao Pharmaceutical's first Sino-US dual-reported drug
.
On July 15, 2019, Yabao Pharmaceutical's sorafenib tablets received the FDA provisional approval number; recently, it was officially approved by the National Medical Products Administration
It is understood that the original research company of sorafenib tablets is Bayer, which is an oral multi-target, multi-kinase inhibitor that can treat renal cell carcinoma, hepatocellular carcinoma and thyroid cancer
.
At present, sorafenib tablets have been approved for marketing in 121 countries around the world, benefiting more than 1 million people, and are unanimously recommended by authoritative guidelines at home and abroad
In recent years, Yabao Pharmaceutical has adhered to its clinical needs as its guidance, internationalization as its leadership, and talents and technology as its driving force, and it has deployed high-tech generic drugs, innovative drugs and biological drugs
.
At present, Yabao Pharmaceutical has invested approximately RMB 27,488,900 in R&D expenses in this product R&D project
